Apnea is experienced by about 10% to 12% of neonates with congenital heart defects treated with alprostadil injection.
Apnea is most often seen in neonates weighing less than 2 kg at birth and usually appears during the first hour of drug infusion. Therefore, respiratory status should be monitored throughout treatment and alprostadil injection should be used where ventilatory assistance is immediately available.